Bipolar disorder Paul Harrison Warneford Hospital Bipolar disorder - - PowerPoint PPT Presentation

bipolar disorder
SMART_READER_LITE
LIVE PREVIEW

Bipolar disorder Paul Harrison Warneford Hospital Bipolar disorder - - PowerPoint PPT Presentation

Bipolar disorder Paul Harrison Warneford Hospital Bipolar disorder guidelines NICE (2014) British Association for Psychopharmacology (Goodwin et al, 2016, J. Psychopharmacol . 30: 495-553) Covers all aspects Independent


slide-1
SLIDE 1

Bipolar disorder

Paul Harrison Warneford Hospital

slide-2
SLIDE 2

Bipolar disorder guidelines

  • NICE (2014)
  • British Association for Psychopharmacology (Goodwin et al,

2016, J. Psychopharmacol. 30: 495-553)

– Covers all aspects – Independent – Available free from website: https://www.bap.org.uk/guidelines

  • Also BAP guidelines for psychotropic prescribing in

pregnancy/breastfeeding (2017), and off-label prescribing (2017)

slide-3
SLIDE 3

Troublesome terms

  • Mania vs hypomania

– Mania = mood elevation etc, with functional impairment. – Hypomania = mood elevation (and increased energy) unequivocal, but it does not cause marked functional impairment – Both need to be present for 7 days (though DSM-5 requires

  • nly 4 days for hypomania)
  • Bipolar I vs Bipolar II

– American (DSM) terms – BD1 = ‘true’ BD, with mania – BD2 = milder BD, with hypomania (and depression).

slide-4
SLIDE 4

Majority of BD presents with one or more depressive episodes first, so how to spot BD?

  • Screening for undiagnosed past hypomania

– Episode(s) of increased energy/disinhibition/reduced sleep/grandiosity/irritability – Out-of-character/caused problems/regretted – How long? – Was patient on an antidepressant/stimulant at the time?

  • Family history of BD
slide-5
SLIDE 5
  • Differential diagnosis

– Borderline PD (emotionally unstable PD) – Cyclothymia – ‘Organic’ bipolar disorder

  • Especially if onset >40, unexpected
  • Steroids, L-DOPA, thyroid, cortical lesions

– Schizoaffective disorder – (A ‘degree’ of BD)

  • Comorbidities/confounders

– The rule not the exception – Alcohol and drugs – Anxiety disorders

  • Often persistent, and not explained by mood
slide-6
SLIDE 6

BD vs borderline PD (BPD)

  • Distinguishing features of BPD

– Personality not illness – Pervasive efforts to avoid abandonment – Features fluctuate in response to relationships, e.g. ‘acting

  • ut’ and anger

– Chronic feeling of emptiness, depressive symptoms, poor self-image – Absence of true hypomanic episodes – (Differences in characteristics of mood instability)

  • Comorbid in 20%

– Worse outcomes – BPD ‘blinds clinician to diagnosis of BD’ (and its therapy) – Presence of BPD increases case for psychotherapy

slide-7
SLIDE 7

Bipolar depression

  • Causes far more morbidity than the manic phase
  • SSRIs (and other antidepressants) are largely ineffective

and may precipitate hypomania or rapid cycling

  • Hence recognition of bipolarity is important, as leads to

different treatment algorithm

  • Clinically similar to unipolar depression, but

– Melancholic, psychotic, or atypical features raise suspicion – Plus family history and past history mentioned earlier

slide-8
SLIDE 8

Fluoxetine +

  • lanzapine

Quetiapine First line Second line Fluoxetine +

  • lanzapine

Lamotrigine Quetiapine Quetiapine + lamotrigine

Drug treatment of bipolar depression

Olanzapine

slide-9
SLIDE 9

Bipolar depression (2)

  • Quetiapine:

– Strong evidence – (A bit) less weight gain/metabolic syndrome than

  • lanzapine

– Anxiety and sedation – Dose varies widely

  • Start low, warn about sedation
  • Often <300mg/d needed
slide-10
SLIDE 10

Bipolar depression (3)

  • Lamotrigine

– Reasonable effect as sole agent – Useful adjunct if first-line Rx ineffective – Well tolerated – But slow titration, risk of Stevens-Johnson syndrome – CHC

  • Reduces lamotrigine levels (so risks of toxicity in pill-free week)
  • Either avoid CHC, or use continuous regimen
slide-11
SLIDE 11

Lamotrigine augments quetiapine in bipolar depression

Lancet Psychiatry 2016:3:31-39 Weeks

NB: Lamotrigine response impaired by folic acid Effective over 12 months: 36% in remission, vs 16% in placebo group

slide-12
SLIDE 12

Psychosocial aspects of BD

  • Psychoeducation

– Identify triggers – Recognise early signs – Early intervention (e.g. sleep hygiene, hypnotics) – Importance of medication, and compliance – Involve family

  • Lifestyle advice

– Regular routines, avoid drugs and alcohol

  • Other formal psychotherapies

– Little evidence (including for CBT)

slide-13
SLIDE 13

Fluoxetine +

  • lanzapine

Quetiapine First line Second line Fluoxetine +

  • lanzapine

Lamotrigine Quetiapine Quetiapine + lamotrigine

Third line Add valproate Lurasidone (not licensed for BD in UK) ECT

Drug treatment of bipolar depression

Olanzapine

Add lithium

NB: Limited evidence for all compared to unipolar depression

Aripiprazole (resistant cases)

slide-14
SLIDE 14

Prophylaxis

  • Consider after a single manic episode, and definitely after two
  • Lithium – remains first line

– Anti-suicidal effect

  • Valproate
  • Lithium + valproate
  • Quetiapine
  • Lamotrigine

– Not good anti-manic

  • Carbamazepine – weak evidence, now rarely used
  • Stopping prophylaxis: difficult decision, often better to

continue

– Always taper very gradually (especially lithium)

  • Naturalistic data interesting…
slide-15
SLIDE 15

JAMA Psychiatry AOL 28.2.18

18,000 BD patients followed for 25 years 9,000 admissions

slide-16
SLIDE 16

Overall, lithium did best

slide-17
SLIDE 17

Quetiapine had only modest benefits – and olanzapine none

slide-18
SLIDE 18

Depot antipsychotics did much better than

  • ral

…compliance

slide-19
SLIDE 19

BD in women of child-bearing age

  • Pros and cons of meds vs no meds, and which one
  • High risk of relapse during and after pregnancy
  • BD itself associated with increased risk of adverse

pregnancy outcomes

  • Ideally, discussion and monitoring pre-conception
  • Avoid valproate
  • Lithium – less risky than thought

– cardiac malformations in 2.4% vs 1.2%

  • Lamotrigine, quetiapine, olanzapine – relatively safe

– as is lithium after first trimester

slide-20
SLIDE 20

Physical health monitoring

  • Same excess mortality and cardiovascular risks as

schizophrenia

  • Physical health checks recommended for mood

stabilisers as for antipsychotics

  • Lithium monitoring (levels, renal, thyroid, calcium)
  • Guidelines and protocols for both are under review
slide-21
SLIDE 21

Services for BD

  • BD omitted from NSF

– Significance and needs neglected – Refer to AMHT or EIS in usual way

  • Specialist BD clinic run at Warneford by academic

psychiatrists

– For research studies, especially clinical trials – Remote mood monitoring – Not an emergency service; not complex or chronic cases – Referrals/queries to oxfordhealth.bipolarclinic@nhs.net – Leaflets

slide-22
SLIDE 22

https://oxfordhealth.truecolours.nhs.uk/www/

slide-23
SLIDE 23

Questions?

slide-24
SLIDE 24
slide-25
SLIDE 25

Lester UK adaptation (2014) RCPsych